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INTRODUCTION
Germline genetic testing of breast cancer patients is an important model of how increasingly 
widespread genomic sequencing can influence treatment decision-making. Testing of two 
breast cancer-associated genes, BRCA1/2, has been available for twenty years, but new 
massively parallel sequencing technology and less restrictive patent laws have made 
multiplex panel tests available at much lower costs.1 Yet little is known about recent patient 
experience with genetic testing and counseling. Genetic counselors are expert in risk 
assessment and communication, but because of workforce limitations, some physicians must 
counsel and test patients without their assistance.2 These challenges motivated this 
investigation of patients’ use of and perspectives on genetic counseling and testing.
METHODS
The study was approved by the University of Michigan Institutional Review Board, which 
waived the requirement of signed informed consent. Women aged 20 through 79 years, 
diagnosed with stages 0–II breast cancer between July 2013 and September 2014, identified 
by Surveillance Epidemiology and End Results registries of Georgia and Los Angeles 
County, were mailed surveys (Supplement) two months after surgery. Questions addressed 
how much patients wanted genetic testing (not at all, a little bit, somewhat, quite a bit, very 
much: the latter 4 were defined as wanting testing); and whether patients talked about testing 
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with any “doctor or other health professional”, had a session with a genetic counseling 
expert, and/or had testing. Cancer family history, ancestry and clinical information were 
used to construct a guideline-concordant measure of high pre-test risk for mutation 
carriage.3 A log-linear model was constructed (SAS Version 9.4, SAS Institute) to compute 
risk ratios, adjusting for covariates (listed in Table 1), and weighted for survey design and 
non response to identify variables independently associated with failure to receive testing 
among high-risk patients.
RESULTS
A total of 2,529 women (71%) responded to the survey. The mean age was 62 years 
(standard deviation 11); 56.8% were white, 17.8% black, and 71.2% had some college 
education (Table 1). Sixty-six percent (95% CI, 64.2%–68.2%) reported wanting testing and 
29.0% (95% CI, 27.1%–30.9%) reported having a test. Thirty-one percent (N=773, 95% CI, 
29.2%–33.1%) of patients had high pre-test mutation risk. Among average-risk patients, 
59.3% (95% CI, 56.8%–61.8%) wanted testing, 35.9% (95% CI, 33.4%–38.3%) reported 
talking about testing with any doctor/health professional, and 17.8% (95% CI, 16.0%–
19.9%) had testing (Table 2). Among high-risk patients, 80.9% (95% CI, 78.0%–83.9%) 
wanted testing, 70.9% (95% CI, 67.5%–74.3%) talked about testing with any doctor/health 
professional, 39.6% (95% CI, 35.9%–43.3%) had a session with a genetic counseling expert, 
and 52.9% (95% CI, 49.1%–56.6%) had testing. Of tested high-risk patients, 61.7% (95% 
CI, 56.6%–66.7%) had an expert genetic counseling session. The most common reason 
high-risk patients reported for not testing was “my doctor didn’t recommend it” (56.1%), 
“too expensive” (13.7%), “I did not want it” (10.7%), and “my family didn’t want me to get 
it” (0.2%). On multivariable analysis (Table 1), characteristics associated with no testing 
included older age and Asian ethnicity but not education, income, or insurance.
DISCUSSION
In this large, population-based study, most patients reported wanting genetic testing and 29% 
reported having it. Yet only 39.6% of all high-risk women and 61.7% of tested high-risk 
women reported having a genetic counseling session. This suggests a gap between need and 
availability of genetic counseling. Only 52.9% of high-risk patients had a genetic test, 
representing a missed opportunity to prevent ovarian and other cancer deaths among 
mutation carriers and their families. High-risk patients most vulnerable to under-testing 
included Asians and older women, despite evidence that many such patients carry 
mutations.4,5
Clinical need for genetic testing may not be adequately recognized by physicians. High-risk 
patients reported lack of a physician’s recommendation, not expense, as their primary reason 
for not testing. Limitations of the study include the testing data source being by patient self-
report and that the patients lived in only 2 geographic regions. The findings emphasize the 
importance of cancer physicians in the genetic testing process. Priorities include improving 
physicians’ communication skills and assessments of patients’ risk and desire for testing, 
and optimizing triage to genetic counselors.
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